Cystic Fibrosis–Related Diabetes: Current Trends in Prevalence, Incidence, and Mortality by Moran, Antoinette et al.
Cystic Fibrosis–Related Diabetes: Current
Trends in Prevalence, Incidence, and
Mortality
ANTOINETTE MORAN, MD
1
JORDAN DUNITZ, MD
2
BRANDON NATHAN, MD
1
ASAD SAEED, MD
2
BONNIE HOLME, BS
1
WILLIAM THOMAS, PHD
3
OBJECTIVE — Cysticﬁbrosis(CF)-relateddiabetes(CFRD)diagnosisandmanagementhave
considerably changed since diabetes was ﬁrst shown to be associated with a poor prognosis in
subjectswithCF.CurrenttrendsinCFRDprevalence,incidence,andmortalityweredetermined
from a comprehensive clinical database.
RESEARCH DESIGN AND METHODS — Data were reviewed from 872 CF patients
followed at the University of Minnesota during three consecutive intervals: 1992–1997, 1998–
2002, and 2003–2008.
RESULTS — CFRD is currently present in 2% of children, 19% of adolescents, and 40–50%
of adults. Incidence and prevalence are higher in female subjects aged 30–39 years; otherwise,
there are no sex differences. Inyounger individuals, CFRD without fasting hyperglycemia predom-
inates, but fasting hyperglycemia prevalence rises with age. CFRD mortality has signiﬁcantly
decreasedovertime.From1992–1997to2003–2008,mortalityrateinfemalesubjectsdropped
by 50% from 6.9 to 3.2 deaths per 100 patient-years and in male subjects from 6.5 to 3.8
deaths per 100 patient-years. There is no longer a sex difference in mortality. Diabetes was
previously diagnosed as a perimorbid event in nearly 20% of patients, but of 61 patients diag-
nosed with diabetes during 2003–2008, only 2 died. Lung function but not nutritional status is
stillworseinCFpatientswithdiabetescomparedwiththosewithoutdiabetes.Nutritionalstatus
andpulmonarystatusaresimilarbetweenpatientswithoutfastinghyperglycemiaandthosewith
fasting hyperglycemia.
CONCLUSIONS — Previously noted sex differences in mortality have disappeared, and the
gap in mortality between CF patients with and without diabetes has considerably narrowed. We
believe that early diagnosis and aggressive treatment have played a major role in improving
survival in these patients.
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D
iabetesisthemostcommoncomor-
bidity in subjects with cystic ﬁbro-
sis (CF). Of particular concern is
the fact that the additional diagnosis of
diabetes has been associated with signiﬁ-
cantly greater mortality, especially in
women. In 1988, we reported that com-
pared with 60% of the nondiabetic CF
population,25%ofindividualswithdi-
abetes survived until age 30 years (1). We
subsequently published data examining
mortality at the University of Minnesota
Cystic Fibrosis Center during the 15-year
period between 1987 and 2002 and
reached the startling conclusion that dia-
betes reduced survival in women by 16
years (2). Unlike the general population,
patients with CF-related diabetes (CFRD)
are not at risk for atherosclerotic cardio-
vascular disease (3); as in other individu-
als with CF, death occurs from chronic
inﬂammatory lung disease. In several
studies, pulmonary function and nutri-
tional status have been shown to be inti-
mately linked and to be worse in patients
with CFRD compared with CF patients
without diabetes (4–8). It has been pos-
tulated that this is a consequence of the
protein catabolic effects of insulin deﬁ-
ciency combined with the proinﬂamma-
tory effects of hyperglycemia.
Since 1987, experimental studies and
careful clinical data collection have pro-
gressively increased our understanding of
CFRD,anditismanagedmuchdifferently
todaythaneven5yearsago.Withroutine
annualoralglucosetolerancetest(OGTT)
outpatientscreeningandcarefulinpatient
glucose monitoring, patients are not
likely to experience long periods of undi-
agnosed diabetes. We are much better
able to accurately report prevalence and
incidence of CFRD, particularly in the
older age-groups, because CF patients
are living longer. Early institution of in-
tensive basal-bolus insulin therapy has
become routine in the last 5 years. Thus,
patients are diagnosed earlier and treated
more aggressively than ever before. The
current database review was undertaken
to determine whether modern diabetes
screening and management have inﬂu-
enced prevalence, incidence, and mortal-
ity ﬁgures.
RESEARCH DESIGN AND
METHODS— Clinical information
was reviewed from a total of 872 patients
followed at the University of Minnesota
Cystic Fibrosis Center from 1 January
1992through15September2008.CFpa-
tientsareroutinelyseenatquarterlyinter-
vals, and patient data are recorded in the
Minnesota Cystic Fibrosis Database. The
information collected includes demo-
graphicandanthropometricdata,pulmo-
nary function tests, other laboratory tests,
data on medication use, and clinical char-
acteristics. All patients followed at this
center gave informed consent permitting
their records to be reviewed for research
purposes.
CFRD diagnosis and management
CFRD is diagnosed by standard criteria
including persistent random glucose lev-
els200mg/dl(11.1mmol/l)andpersis-
tent fasting glucose levels 126 mg/dl
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OGTT screening has been recommended
at the University of Minnesota since the
early 1990s for patients aged 6 years
(1.75 g/kg glucose [maximum 75g]).
OGTTs are performed when patients are
intheirusualbaselinestateofhealth.Sub-
jects are classiﬁed based on standards
adopted by the 1998 CFRD consensus
guidelines (9). Patients with a fasting glu-
cose 126 mg/dl (7.0 mmol/l) have
CFRD with fasting hyperglycemia, while
those with a fasting glucose 126 mg/dl
(7.0 mmol/l) and a 2-h glucose 200
mg/dl (11.1 mmol/l) have CFRD without
fasting hyperglycemia.
Diabetes management follows a uni-
form protocol that includes the involve-
ment of an endocrinologist, a diabetes
nurse educator, and a dietitian. Prior to
2003, the most common insulin regimen
for patients with fasting hyperglycemia
was a single injection of NPH insulin at
bedtime and three to four injections of
regularinsulin(before2000)orfourtosix
injections of rapid-acting insulin (after
2000) with meals. Patients without fast-
ing hyperglycemia were seldom treated
with insulin. Since 2003, basal-bolus in-
sulintherapyhasbeenstandardforCFRD
with fasting hyperglycemia, using either
an insulin pump or multiple daily injec-
tions including basal insulin. Patients
without fasting hyperglycemia have been
encouraged to use premeal rapid-acting
insulin. Hospitalized patients are now
routinely treated with insulin if they are
hyperglycemic; the need for persistent in-
sulin is then reevaluated once they are
clinically well.
Database review
In order to examine temporal changes, the
data were examined for three consecutive
intervals: 1 January 1992 through 31 De-
cember 1997, 1 January 1998 through 31
December 2002, and 1 January 2003
through 15 September 2008. All patients
seen in a clinic during an interval were in-
cludedincalculationsforthatinterval.Date
ofdiabetesdiagnosiswastheearlierdatefor
either starting insulin based on clinical cri-
teriaoranOGTTresultdiagnosticofdiabe-
tes. Percent predicted forced expiratory
volume in 1 s (FEV1) was the last recorded
value before 15 September 2008.
Analytic methods
Prevalence percents and counts were com-
pared between groups with logistic regres-
sion. Incidence and mortality rates were
Figure 1—Current prevalence of CFRD in the 527 patients actively followed at the University of
Minnesota, 15 September 2008. A: CFRD total (f), CFRD with fasting hyperglycemia (o), and
CFRDwithoutfastinghyperglycemia( )bydecadeofage.B:CFRDtotalmen(f)versuswomen
( ) by decade of age. The number of total subjects (with and without diabetes) in each age-group
is noted. *P  0.02, men vs. women.
Table 1—Mortality rates and CFRD prevalence and incidence for consecutive time intervals
19921997 19982002 20032008
Patients seen in a clinic during the interval 752 702 647
Female subjects (%) 53 53 53
CFRD prevalence at the end of the interval (%) 20  2a 30  2b 33  2b
CFRD incidence per 100 person-years 3.0  0.3a 4.0  0.4b 2.7  0.3a
CFRD mortality rate per 100 person-years 6.7  1.3a 5.4  0.9a 3.5  0.6b
Patients diagnosed with CFRD during the
interval/those who were diagnosed and died
within the same interval 108/18a 102/12a 61/2b
Total CF population mortality rate per 100
person-years 1.2  0.2 1.6  0.2 1.8  0.2
Non-CFRD mortality rate per 100 person-
years 0.5  0.1a 0.6  0.2ab 1.0  0.2b
Data are means  SE unless otherwise indicated. a, b Comparisons are between time intervals within each
row. Rates that do not share a letter are signiﬁcantly different (P  0.05); rates that share a letter are not
signiﬁcantly different. Rows with no letters have no signiﬁcant differences. During each interval, for all rates
there were no signiﬁcant differences between male and female subjects.
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berofeventsduringatimeintervalandmis
the total time at risk of the event during the
interval from all individuals. Under a Pois-
son model, the SE of the rate is d/m. Inci-
dence and mortality rates were compared
between groups with Poisson regression.
All analyses were performed with SAS (ver-
sion 9.2; SAS Institute, Cary, NC).
RESULTS
CFRD prevalence
In September 2008, there were 527 pedi-
atric and adult patients actively followed
at the University of Minnesota Cystic Fi-
brosis Center. Of these, 33% had diabe-
tes—the ﬁgure similar to the 30% at the
end of 2002 but showing a signiﬁcant in-
crease from the 20% of patients known to
havediabetesattheendof1997(Table1).
In all three periods, the prevalence of di-
abetesrosesteadilywithagethroughthe
30–39 age decade and after the age of
40 years remained at 45–50% (Fig. 1A).
In younger individuals, CFRD without
fasting hyperglycemia predominated;
however, the prevalence of fasting hy-
perglycemia rose steadily with age so that
thepercentageofCFRDpatientswithand
without fasting hyperglycemia was ap-
proximately equal for individuals in their
30s, and after the age of 40 years, CFRD
with fasting hyperglycemia predomi-
nated. In 2008, female subjects had sig-
niﬁcantly higher diabetes prevalence in
the30–39agedecadethanmalesubjects,
but otherwise no sex differences in prev-
alence were present (Fig. 1B).
CFRD incidence
Whilediabetesprevalencerose,incidence
fell signiﬁcantly: from four cases per 100
patient-years during the 1998–2002 in-
terval to 2.7 cases per 100 patient-years
during 2003–2008, representing a 40%
decrease in the number of diabetes diag-
noses (Table 1). The decrease in inci-
dence occurred for both male and
female subjects, with a larger decrease
in female subjects. During the 1990s,
annual OGTT surveillance was just be-
ing established as the standard; thus,
many of those receiving a new diagnosis
of diabetes at their ﬁrst screening may
have had the disease for some time, in-
ﬂating incidence. Currently, a peak in
incidence is noted in women aged
30–39 years (Fig. 2).
CFRD mortality
Theincreaseindiabetesprevalencewitha
decrease in diabetes incidence resulted
from a signiﬁcant decrease in mortality in
patients with diabetes. From 1992–1997
to 2003–2008, mortality in female sub-
jects with diabetes dropped by 50%,
from 6.9 to 3.2 deaths per 100 patient-
years, and the decrease in male subjects
wasnearlyaslarge,from6.5to3.8deaths
per 100 patient-years (Table 1). During
the earlier two time periods, diabetes was
frequently diagnosed as a perimorbid
event. Of 108 patients diagnosed with di-
abetesduring1992–1997,18diedduring
thatsameinterval,andresultswerenearly
identical during 1998–2002. During
2003–2008, 61 patients were diagnosed
with diabetes, of whom only 2 died dur-
ing the interval.
Mortality is shown in Fig. 3 by diabe-
tes status, sex, and age decade over the
three time intervals. Over time, there has
been a steady decrease in mortality in CF
patients with diabetes. In the most recent
time period, overall mortality still re-
mained signiﬁcantly higher in those with
CFRD compared with those without dia-
betes, but the gap has considerably nar-
rowed compared with the earlier time
periods.Importantly,during2003–2008,
sex differences in mortality by diabetes
status appear to have disappeared.
Clinical characteristics of the 2008
CFRD patient cohort
In September 2008, only 2 of 93 children
aged 11 years had diabetes (a boy and a
girl both without fasting hyperglycemia).
Figure 2—The University of Minnesota CFRD incidence per 100 patient-years by sex and age decade 2003–2008. Sample sizes for the incidence
rates are shown below the ﬁgure.
CFRD prevalence, incidence, and mortality
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had diabetes (6 girls and 8 boys [4 of the
girls and 1 of the boys with fasting hyper-
glycemia]). There was a trend toward
lower percent predicted FEV1 in those
withdiabetes,butthisdidnotachievesta-
tistical signiﬁcance in this age-group
(83  29 vs. 95  17; P  0.055). CF
adolescents were generally normally
nourished, and there were no signiﬁcant
differencesinBMIpercentile(4727vs.
51  25 kg/m
2; P  0.65) or BMI z-score
(0.1  0.9 vs. 0.0  0.8; P  0.6) be-
tween those with and without CFRD.
Among the 14 adolescents with CFRD,
there were no signiﬁcant differences in
pulmonary or nutritional end points be-
tween those with and without fasting
hyperglycemia.
Mortality has previously been shown
to be greater in adult CF patients with
diabetes; the adult data are shown in Ta-
ble 2. Of subjects aged 18 years, 155 of
359 (43%) had diabetes, half with and
halfwithoutfastinghyperglycemia.There
was no difference in age or nutritional
status between subjects with and with-
out diabetes. Lung function, however,
was signiﬁcantly worse in subjects with
diabetes (percent predicted FEV1 65 
24 vs. 71 24,P  0.05). Surprisingly,
thismeandifferencewasalmostentirely
a result of worse lung function in male
subjects. Among diabetic subjects,
those with fasting hyperglycemia
tendedtobeolder,withlongerduration
of diabetes but with similar nutritional
statusandFEV1thanthosewithoutfast-
ing hyperglycemia.
Figure 3—The University of Minnesota CFRD and CF mortality per 100 patient-years by sex and age decade over three time periods: 2003–2008,
1998–2002, and 1992–1997. CF patients with diabetes (DM) are shown with solid lines, while CF patients without diabetes are shown with dashed
lines.Zeroratesestimatedfrom10patientsarenotshown.Thegapinmortalitybetweenthosewithandthosewithoutdiabeteshasdiminishedover
these time periods, and the sex difference in mortality has disappeared in the most current analysis.
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currently followed at the University of
Minnesota Cystic Fibrosis Center are well
characterized with regard to diabetes
prevalence, incidence, and mortality.
CFRD is present in 2% of children, 19%
ofadolescents,40%ofindividualsintheir
20s, and 45–50% of those aged 30
years. In the age-group of 30–39 years,
women with CFRD outnumber men, but
otherwise we do not observe a sex differ-
ence in prevalence. Incidence is 2.7 cases
per 100 patient-years, with the exception
of women in their 30s, in whom the inci-
dence more than doubles. Although mor-
tality is still greater in CF patients who
develop diabetes, over the last 15 years
this difference has steadily and markedly
diminished, and the previously noted sex
difference in mortality appears to have
completely disappeared.
Since 1988, several reports have doc-
umented worse clinical status in CF pa-
tients who developed diabetes. Both a
2005NorthAmericanreviewof8,247CF
patients(8)anda2001Europeanstudyof
7,500 patients (6) found that CFRD was
associated with more severe pulmonary
disease and worse nutritional status, and
this ﬁnding was also documented in mul-
tiple smaller studies (1,4,5,7). This has
been postulated to be related to both in-
sulin deﬁciency (with resultant protein
catabolism and malnutrition) and the
inﬂuence of hyperglycemia on inﬂamma-
tion and infection. The current assess-
ment demonstrates that although we still
ﬁnd worse lung function in patients with
CFRD, the mortality associated with this
condition has steadily and substantially
decreased over time. We speculate that
this is related to both earlier detection of
diabetes and more aggressive treatment.
CFRD is generally clinically silent and
only detected by screening. In the past,
diabetes was often diagnosed in patients
with existing but previously undetected
(and untreated) disease, often in the peri-
morbid period. Routine screening now
ensures that diabetes is detected early in
its course.
CFRD treatment is also much more
aggressive today than in the past. The
goals of treatment are to achieve near-
normalization of blood glucose levels and
to deliver as much insulin as possible
without producing hypoglycemia in or-
der to maximize the anabolic effects of
insulin. At the time of the last CFRD con-
sensus conference in 1998, it was not
clear whether CFRD without fasting hy-
perglycemiawasamilderformofdiabetes
requiring less intensive treatment. The
current assessment suggests that pulmo-
nary and nutritional parameters do not
differ by fasting glucose status and that
patients without fasting hyperglycemia
are not “less sick” than those with fasting
hyperglycemia. The standard of care at
the University of Minnesota is now insu-
lin therapy for CFRD patients with and
without fasting hyperglycemia.
WhentheUniversityofMinnesotaCF
mortality data from 1987 to 2002 were
previously analyzed (2), women with CF
and diabetes had dramatically worse sur-
vival. This could not be explained by age,
age of diagnosis of CF or diabetes, A1C,
BMI, pregnancy, glucocorticoid use, mi-
croorganism colonization, or genotype. A
sex difference was also found in a multi-
center British study that reported worse
lung function in women with CF and di-
abetes (10). We speculated that diabetes
might exacerbate CF-related pulmonary
inﬂammation and protein catabolism and
that the presence of anabolic steroids
might offer men natural protection from
the catabolic effects of these two diseases.
With modern intensive diabetes treat-
ment, the sex difference in mortality ap-
pears to have disappeared.
In summary, diabetes is an expected
complicationasindividualswithCFgrow
older. It is encouraging to note that pre-
vious sex differences in mortality have
disappeared and that the gap in mortality
betweenCFpatientswithdiabetesandCF
patients without diabetes has consider-
ably narrowed. Although many factors
have changed in the management of indi-
viduals with CF over the last decade, we
believethatearlydiagnosisandaggressive
treatment of CFRD have played a major
role in improving survival in these
patients.
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